2
1/16/2017 Navdeep Pal - Google Scholar Citations https://scholar.google.com/citations?user=lQ3-LBMAAAAJ&hl=en&oi=ao 1/2 Navdeep Pal McKesson Specialty Health Statistics, Data Science, Clinical Research Google Scholar Citation indices All Since 2012 Citations 39 39 hindex 3 3 i10index 2 2 Title 1–17 Cited by Year Overall survival after pelvic exenteration for gynecologic malignancy SN Westin, V Rallapalli, B Fellman, DL Urbauer, N Pal, MM Frumovitz, ... Gynecologic oncology 134 (3), 546551 21 2014 PTEN loss is a contextdependent outcome determinant in obese and nonobese endometrioid endometrial cancer patients SN Westin, Z Ju, RR Broaddus, C Krakstad, J Li, N Pal, KH Lu, ... Molecular oncology 9 (8), 16941703 10 2015 Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. SN Westin, ML Smart, N Pal, DL Urbauer, F Janku, JJ Wheler, ... ASCO Annual Meeting Proceedings 31 (15_suppl), 2611 3 2013 Prospective phase II trial of the Levonorgestrel Intrauterine System (Mirena) to treat complex atypical hyperplasia and grade 1 endometrioid endometrial cancer S Westin, C Sun, R Broaddus, N Pal, V Nath, D Urbauer, K Schmeler, ... Gynecologic Oncology 125, S9 3 2012 Challenging the paradigm of progesteroneonly therapy for early endometrial cancer: Results of a prospective trial of the levonorgestrel intrauterine system SN Westin, CCL Sun, R Broaddus, N Pal, M Woodall, D Urbauer, ... Gynecologic Oncology 141, 1819 1 2016 PTEN loss as a contextdependent determinant of patient outcomes in obese and nonobese endometrioid endometrial cancer patients. Z Ju, SN Westin, R Broaddus, J Li, N Pal, KH Lu, RL Coleman, ... ASCO Annual Meeting Proceedings 31 (15_suppl), 5521 1 2013 Obesity significantly reduces the sentinel lymph node detection rate in women with endometrial cancer PT Soliman, AM Nick, CCL Sun, S Dioun, N Pal, M Abdelwahab, ... Gynecologic Oncology 141, 31 2016 PHASE I TRIAL OF CARBOPLATIN, BEVACIZUMAB, AND TEMSIROLIMUS IN ADVANCED SOLID TUMORS S Westin, M Castaneda, N Pal, D Urbauer, F Janku, J Wheler, S PihaPaul, ... INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 25 (9), 365365 2015 Sa1416 Differences in ERCP Related Practice Patternsan Electronic Survey G Syal, N Pal, R Rego, S Dang Gastrointestinal Endoscopy 81 (5), AB205AB206 2015 Platinumfree interval is a predictor of survival for recurrent, advancedstage uterine papillary serous carcinoma LL Holman, LE Dockery, PT Soliman, N Pal, AH Klopp, R Broaddus, ... Gynecologic Oncology 137, 159160 2015

Navdeep Pal - Google Scholar Citations

Embed Size (px)

Citation preview

Page 1: Navdeep Pal - Google Scholar Citations

1/16/2017 Navdeep Pal - Google Scholar Citations

https://scholar.google.com/citations?user=lQ3-LBMAAAAJ&hl=en&oi=ao 1/2

Navdeep PalMcKesson Specialty HealthStatistics, Data Science, Clinical Research

Google ScholarCitation indices All Since 2012Citations 39 39hindex 3 3i10index 2 2

Title 1–17 Cited by Year

Overall survival after pelvic exenteration for gynecologic malignancySN Westin, V Rallapalli, B Fellman, DL Urbauer, N Pal, MM Frumovitz, ...Gynecologic oncology 134 (3), 546551

21 2014

PTEN loss is a contextdependent outcome determinant in obese and nonobeseendometrioid endometrial cancer patientsSN Westin, Z Ju, RR Broaddus, C Krakstad, J Li, N Pal, KH Lu, ...Molecular oncology 9 (8), 16941703

10 2015

Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors.SN Westin, ML Smart, N Pal, DL Urbauer, F Janku, JJ Wheler, ...ASCO Annual Meeting Proceedings 31 (15_suppl), 2611

3 2013

Prospective phase II trial of the Levonorgestrel Intrauterine System (Mirena) to treatcomplex atypical hyperplasia and grade 1 endometrioid endometrial cancerS Westin, C Sun, R Broaddus, N Pal, V Nath, D Urbauer, K Schmeler, ...Gynecologic Oncology 125, S9

3 2012

Challenging the paradigm of progesteroneonly therapy for early endometrialcancer: Results of a prospective trial of the levonorgestrel intrauterine systemSN Westin, CCL Sun, R Broaddus, N Pal, M Woodall, D Urbauer, ...Gynecologic Oncology 141, 1819

1 2016

PTEN loss as a contextdependent determinant of patient outcomes in obese andnonobese endometrioid endometrial cancer patients.Z Ju, SN Westin, R Broaddus, J Li, N Pal, KH Lu, RL Coleman, ...ASCO Annual Meeting Proceedings 31 (15_suppl), 5521

1 2013

Obesity significantly reduces the sentinel lymph node detection rate in women withendometrial cancerPT Soliman, AM Nick, CCL Sun, S Dioun, N Pal, M Abdelwahab, ...Gynecologic Oncology 141, 31

  2016

PHASE I TRIAL OF CARBOPLATIN, BEVACIZUMAB, AND TEMSIROLIMUS INADVANCED SOLID TUMORSS Westin, M Castaneda, N Pal, D Urbauer, F Janku, J Wheler, S PihaPaul, ...INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER 25 (9), 365365

  2015

Sa1416 Differences in ERCP Related Practice Patternsan Electronic SurveyG Syal, N Pal, R Rego, S DangGastrointestinal Endoscopy 81 (5), AB205AB206

  2015

Platinumfree interval is a predictor of survival for recurrent, advancedstage uterinepapillary serous carcinomaLL Holman, LE Dockery, PT Soliman, N Pal, AH Klopp, R Broaddus, ...Gynecologic Oncology 137, 159160

  2015

Page 2: Navdeep Pal - Google Scholar Citations

1/16/2017 Navdeep Pal - Google Scholar Citations

https://scholar.google.com/citations?user=lQ3-LBMAAAAJ&hl=en&oi=ao 2/2

Title 1–17 Cited by Year

Factors prognostic of survival in advanced stage uterine papillary serous carcinomaN PalTHE UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH

  2015

Importance of platinum sensitivity and treatment modality in advancedstage uterinepapillary serous carcinomaL Holman, P Soliman, N Pal, N Balakrishnan, A Klopp, R Broaddus, ...Gynecologic Oncology 130 (1), e79

  2013

Neoadjuvant chemotherapy in stage IV uterine papillary serous carcinomaL Holman, P Soliman, N Pal, H Mhadgut, A Klopp, R Broaddus, N Fleming, ...Gynecologic Oncology 130 (1), e82

  2013

KRAS mutation in endometrial and ovarian cancers: Preliminary data on associationwith phenotype and clinical outcome in primary diseaseS Westin, C Sun, N Pal, F Janku, A Tsimberidou, G Falchook, D Hong, ...Gynecologic Oncology 130 (1), e162

  2013

Pathologic distribution of disease at the time of interval debulking versus primarytumor reduction in women with primary peritoneal, ovarian, or Fallopian tubecarcinoma.TM Zaid, M Huang, AJ Brown, N Balakrishnan, H Mhadgut, N Pal, C Wei, ...ASCO Annual Meeting Proceedings 31 (15_suppl), 5584

  2013

Longterm survival in advancedstage uterine papillary serous carcinoma.LL Holman, DA Iglesias, PT Soliman, N Pal, A Klopp, R Broaddus, T Ayeni, ...ASCO Annual Meeting Proceedings 31 (15_suppl), 5596

  2013

Retrospective assesment of the levonorgestrel intrauterine device to treat complexatypical hyperplasia and early endometrioid endometrial cancerN Pal

  2012

Dates and citation counts are estimated and are determined automatically by a computer program.